TD Cowen analyst Tyler Van Buren has maintained their bullish stance on TYRA stock, giving a Buy rating today.
Tyler Van Buren has given his Buy rating due to a combination of factors, primarily focusing on Tyra Bioscience’s promising clinical developments and strong financial position. The company is advancing its clinical trials with TYRA-300 and TYRA-430, targeting various conditions such as achondroplasia and non-muscle invasive bladder cancer, which are expected to yield positive outcomes based on previous data.
Additionally, Tyra Bioscience’s financial health is robust, providing sufficient runway to support these clinical programs. The impressive results from the SURF301 trial, where TYRA-300 demonstrated a higher objective response rate compared to existing treatments, further solidify the company’s potential for success. These strategic advancements and financial stability underpin Van Buren’s optimistic outlook on Tyra Bioscience’s stock, justifying the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.